HGS Wastes No Time Investing In Pipeline Beyond Benlysta
This article was originally published in The Pink Sheet Daily
Executive Summary
One week after receiving FDA approval for its breakthrough lupus drug, Human Genome Sciences is spending $50 million for broad rights to an early-stage cancer drug that hits a popular target.